However, stimulation of NSCLC cell lines with CDK2 or CDK4/6 inhibitors resulted in decreased amounts of pSMAD2L+ and pHH3+ cells in G2/M (Fig. 2m–o and r–t) and was validated by analysing double positive cell counts in different cell lines, independent of cell cycle phases. This evidence concerns the gene CDK2 and non-small cell lung carcinoma.